ADP Ribose Transferases

• 

  Subject Areas on Research

  • A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. 
  • Cellular cytoskeleton dynamics modulates non-viral gene delivery through RhoGTPases 
  • Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis. 
  • Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck. 
  • Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. 
  • Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. 
  • Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. 
  • Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation. 
  • Inhibition of Rho-kinase induces alphaB-crystallin expression in lens epithelial cells. 
  • Ligation of low-density lipoprotein receptor-related protein with antibodies elevates intracellular calcium and inositol 1,4, 5-trisphosphate in macrophages. 
  • Modulation of Rho GTPase activity alleviates chondroitin sulfate proteoglycan-dependent inhibition of neurite extension. 
  • Nicotinamide adenine dinucleotide (NAD) and its metabolites inhibit T lymphocyte proliferation: role of cell surface NAD glycohydrolase and pyrophosphatase activities. 
  • Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy. 
  • Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial. 
  • Pseudomonas exotoxin A mutants. Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. 
  • Receptor-associated protein binding blocks ubiquitinylation of the low density lipoprotein receptor-related protein. 
  • Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. 
  • Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation. 
  • Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. 
  • The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes. Involvement of Rho kinase.